Algert Global’s Tvardi Therapeutics TVRD Stock Holding History

Algert Global’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,632	Closed	-$99K	–	1284
2023 Q3	$99K	Buy	+1,632	New	+$153K	﹤0.01%	1031

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Algert Global's TVRD Position: Q4 2023 in Review

Algert Global sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 1,632 shares — an estimated $99K sold.

Algert Global first reported a position in TVRD in Q3 2023 and held it in 1 quarter. The position peaked at $99K in Q3 2023. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

Algert Global reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
Algert Global sold 1,632 Tvardi Therapeutics shares in Q4 2023, an estimated $99K.
Algert Global first reported a position in Tvardi Therapeutics in Q3 2023 and held it in 1 quarter.
Algert Global's Tvardi Therapeutics position peaked at $99K in Q3 2023.
109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on Algert Global's 13F filing for Q4 2023, filed 14 Feb 2024.